Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Federico, De Marchi"'
Autor:
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li
Publikováno v:
Cancer Medicine, Vol 9, Iss 12, Pp 4386-4394 (2020)
Abstract Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell
Externí odkaz:
https://doaj.org/article/d4066f83fadc406b860f4b17fa765af8
Autor:
Rena Xian, Federico De Marchi, Peter B. Illei, Deborah A. Belchis, Jialing Haung, Christopher D. Gocke, Erika F. Rodriguez, James R. Eshleman, Li Hui Tseng, Ming Tseh Lin
Publikováno v:
Molecular Diagnosis & Therapy. 24:461-472
Differentiation between intrapulmonary metastasis (IPM) and multiple primary lung cancers (MPLC) in patients with synchronous or metachronous lung tumor nodules is critical but challenging. We proposed an algorithm to evaluate clonal origin based on
Autor:
Massimiliano Bonifacio, Gianni Binotto, Elena Maino, Elisabetta Calistri, Luciana Marin, Luigi Scaffidi, Luca Frison, Federico De Marchi, Mauro Krampera, Giampiero Semenzato, Renato Fanin, Achille Ambrosetti, Mario Tiribelli
Publikováno v:
Haematologica, Vol 100, Iss 8 (2015)
Externí odkaz:
https://doaj.org/article/8de6d8f9804c48b2a1d3049f69176ffa
Publikováno v:
Expert Review of Hematology. 12:285-293
Acute megakaryoblastic leukemia (AMegL) is a rare hematological neoplasm most often diagnosed in children and is commonly associated with Down's syndrome (DS). Although AMegLs are specifically characterized and typically diagnosed by megakaryoblastic
Autor:
Federico, De Marchi, Maho, Okuda, Soji, Morishita, Misa, Imai, Terumi, Baba, Mei, Horino, Yosuke, Mori, Chiho, Furuya, Satoko, Ogata, Yinjie, Yang, Jun, Ando, Miki, Ando, Marito, Araki, Norio, Komatsu
Publikováno v:
Leukemia Research. 119:106883
Cyclic AMP-response element-binding protein 3-like 1 (CREB3L1) is a gene involved in the unfolded protein response (UPR). Recently, we demonstrated that CREB3L1 is specifically overexpressed in the platelets of patients with Philadelphia chromosome-n
Autor:
Lukasz P. Gondek, Peter D. Aplan, Luigi Marchionni, Amy E. DeZern, Francisco Pereira Lobo, Douglas B. Smith, Federico De Marchi, Bonnie W. Lau, Kyounghee Huh, Mark J. Levis, Qiuju Wang, William Matsui, Rafael Madero-Marroquin, Yiting Lim
Publikováno v:
Oncogene. 38:687-698
Myelodysplastic syndromes (MDSs) are stem cell disorders with risk of transformation to acute myeloid leukemia (AML). Gene expression profiling reveals transcriptional expression of GLI1, of Hedgehog (Hh) signaling, in poor-risk MDS/AML. Using a muri
Autor:
Jiang Gui, Natalia H. Zbib, Rafael Madero-Marroquin, William Matsui, Federico De Marchi, Bonnie W Lau, Alyza M. Skaist, Shiyu Wang, Lukasz P. Gondek
Publikováno v:
European Journal of Haematology. 107:293-294
Autor:
Maria Vittoria Dubbini, Carla Filì, Renato Fanin, Federico De Marchi, Nicholas Rabassi, Maria Elena Zannier, Davide Lazzarotto, Anna Candoni, Eleonora Toffoletti, Bonnie W. Lau
Publikováno v:
Leukemia Research. 63:22-27
We analyzed the outcome of allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML) patients according to molecular Minimal Residual Disease (MRD) status prior to allo-SCT. MRD was assessed by the quantitative expression of the
Autor:
Julie R. Brahmer, James R. Eshleman, Ming Tseh Lin, Gang Zheng, Federico De Marchi, Frederic B. Askin, Stacy Riel, Peter B. Illei, Li Hui Tseng, Doreen Nguyen, Patrick M. Forde, Deborah A. Belchis, Christopher D. Gocke, Katie Beierl, Lisa Haley
Publikováno v:
Oncotarget
// Peter B. Illei 1, * , Deborah Belchis 1, * , Li-Hui Tseng 1, 2 , Doreen Nguyen 1 , Federico De Marchi 1, 3 , Lisa Haley 1 , Stacy Riel 1 , Katie Beierl 1 , Gang Zheng 1 , Julie R. Brahmer 4 , Frederic B. Askin 1 , Christopher D. Gocke 1, 4 , James
Autor:
Erika F. Rodriguez, Rena Xian, Parvez M. Lokhandwala, James R. Eshleman, Deborah A. Belchis, Federico De Marchi, Ming Tseh Li, Christopher D. Gocke, Peter B. Illei
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 12, Pp 4386-4394 (2020)
Cancer Medicine, Vol 9, Iss 12, Pp 4386-4394 (2020)
Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell lung can